Inside the Lemonaid Health Buy: Kyle Pretsch on Bambu Ventures’s Bold Play
Bambu Ventures's Kyle Pretsch dives into Lemonaid’s $10M buyout, down from 23andMe’s $400M price tag, and what’s next after Chrome Co.’s dramatic pivot.
More Videos
Beyond Ozempic: Why Silicon Valley Is Turning to Experimental Peptides
Jasmine Sun on unregulated peptides moving from fringe biohacking to Silicon Valley mainstream, promising healing, focus, and optimization with little oversight
Go Fund Yourself: The Next Wave of Tech and Design
AtomBeam Technologies is transforming data transmission, while Twist Brite reimagines lighting with a simple twist.
How Market Reactions Influence Trump’s Decision-Making
For Trump, markets matter more than polls. Luke Broadwater, White House correspondent for The New York Times, examines how Wall Street guides decisions.
Citizenship in Flux: Why Americans Are Looking Abroad
As political and economic uncertainty rises, Americans are seeking second passports and golden visas. Latitude Group’s CEO explains what’s driving the surge.
Inside the Push to Bring Air Taxis to City Skies
Electric air taxis are moving closer to real-world use. Vertical Aerospace’s CEO explains how EVTOLs could transform urban travel and ease congestion.
From Davos to Data Centers: Nuclear Energy’s New Moment
As AI and electrification drive record power demand, nuclear energy returns to the spotlight. Lightbridge CEO explains how advanced fuel could reshape the grid.
